The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia
出版年份 2020 全文链接
标题
The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia
作者
关键词
-
出版物
Frontiers in Oncology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-04-01
DOI
10.3389/fonc.2020.00393
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia
- (2019) Charyguly Annageldiyev et al. HAEMATOLOGICA
- Downregulation of CD73 associates with T cell exhaustion in AML patients
- (2019) Yaxian Kong et al. Journal of Hematology & Oncology
- Loss of KDM6A confers drug resistance in acute myeloid leukemia
- (2019) Sophie M. Stief et al. LEUKEMIA
- Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression
- (2018) Kinjal Shah et al. Clinical Epigenetics
- Understanding of leukemic stem cells and their clinical implications
- (2017) Xuefei Wang et al. Molecular Cancer
- Combination therapy in combating cancer
- (2017) Reza Bayat Mokhtari et al. Oncotarget
- Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia
- (2017) M. Ryan Corces et al. Frontiers in Oncology
- Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells
- (2017) Jun Ma et al. Scientific Reports
- Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
- (2016) Brittany Knick Ragon et al. AMERICAN JOURNAL OF HEMATOLOGY
- Evolution of acute myelogenous leukemia stem cell properties after treatment and progression
- (2016) T.-C. Ho et al. BLOOD
- The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells
- (2016) Annette Brenner et al. MOLECULES
- SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia
- (2016) Constanze Schneider et al. NATURE MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
- (2016) O Lindblad et al. ONCOGENE
- ‘Acute myeloid leukemia: a comprehensive review and 2016 update’
- (2016) I De Kouchkovsky et al. Blood Cancer Journal
- Acute Myeloid Leukemia: A Concise Review
- (2016) Jennifer Saultz et al. Journal of Clinical Medicine
- Comment on: ‘Guidelines for the use of cell lines in biomedical research’: human-to-human cancer transmission as a laboratory safety concern
- (2015) Y Lazebnik et al. BRITISH JOURNAL OF CANCER
- CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia
- (2015) Masayuki Iwasaki et al. Cell Stem Cell
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Andrographolide Analogue Induces Apoptosis and Autophagy Mediated Cell Death in U937 Cells by Inhibition of PI3K/Akt/mTOR Pathway
- (2015) Deepak Kumar et al. PLoS One
- Identification of small molecules that support human leukemia stem cell activity ex vivo
- (2014) Caroline Pabst et al. NATURE METHODS
- Correction: The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer
- (2013) Joshua E. Allen et al. PLoS One
- The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
- (2012) Kiyotaka Kawauchi et al. Anti-Cancer Agents in Medicinal Chemistry
- The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia
- (2011) R. Polak et al. BLOOD
- The Akt Inhibitor ISC-4 Activates Prostate Apoptosis Response Protein-4 and Reduces Colon Tumor Growth in a Nude Mouse Model
- (2011) A. K. Sharma et al. CLINICAL CANCER RESEARCH
- Melanoma Chemoprevention in Skin Reconstructs and Mouse Xenografts Using Isoselenocyanate-4
- (2010) N. Nguyen et al. Cancer Prevention Research
- TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
- (2010) Yoshikane Kikushige et al. Cell Stem Cell
- Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice
- (2009) M. G. Kharas et al. BLOOD
- Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells
- (2009) Liqing Jin et al. Cell Stem Cell
- Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates
- (2009) A. Sharma et al. CLINICAL CANCER RESEARCH
- Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia
- (2009) Alberto M Martelli et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance
- (2009) Ayman Khdair et al. JOURNAL OF CONTROLLED RELEASE
- Stem cell concepts renew cancer research
- (2008) J. E. Dick BLOOD
- Synthesis and Anticancer Activity Comparison of Phenylalkyl Isoselenocyanates with Corresponding Naturally Occurring and Synthetic Isothiocyanates
- (2008) Arun K. Sharma et al. JOURNAL OF MEDICINAL CHEMISTRY
- Comparative Proteomic Phenotyping of Cell Lines and Primary Cells to Assess Preservation of Cell Type-specific Functions
- (2008) Cuiping Pan et al. MOLECULAR & CELLULAR PROTEOMICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search